SELLAS Life Sciences Group, Inc. operates as a clinical stage biopharmaceutical company, which focuses on the development and commercialization of novel cancer immunotherapeutics for cancer indications. Its product galinpepimut-S, or GPS, is an immunotherapeutic agent licensed from Memorial Sloan Kettering Cancer Center, or MSK, which targets the Wilms tumor 1, or WT1, protein. Its products include galinpepimut-S and nelipepimut-S. The company was founded on April 3, 2006 and is headquartered in New York, NY.
Company profile
Website
CEO
Angelos M. Stergiou
Employees
Incorporated
Location
Fiscal year end
Former names
Seligman LaSalle International Real Estate Fund, Inc.
SEC CIK
Latest filings (excl ownership)
N-PX
Annual report of proxy voting record
29 Aug 11
25-NSE
Exchange delisting
14 Apr 11
8-K
Regulation FD Disclosure
8 Apr 11
8-K
Regulation FD Disclosure
18 Mar 11
N-CSR
Certified annual shareholder report (management investment company)
11 Mar 11
8-K
Regulation FD Disclosure
4 Mar 11
8-K
Voting Results of Special Meeting of Stockholders of Riversource Lasalle International Real Estate Fund
22 Feb 11
8-K
Regulation FD Disclosure
15 Feb 11
8-K
Regulation FD Disclosure
18 Jan 11
8-K
Riversource Lasalle International Real Estate Fund, Inc. Declares Fourth Quarter Distribution
3 Dec 10
Latest ownership filings
SC 13D/A
WESTERN INVESTMENT LLC
19 Apr 11
SC 13D/A
Bulldog Investors
4 Apr 11
SC 13D/A
Bulldog Investors
14 Mar 11
SC 13D/A
Bulldog Investors
20 Jan 11
SC 13D/A
Bulldog Investors
17 Nov 10
SC 13D/A
Bulldog Investors
23 Aug 10
SC 13D
Bulldog Investors
23 Jul 10
SC 13D/A
WESTERN INVESTMENT LLC
15 Jul 10
SC 13D
WESTERN INVESTMENT LLC
2 Jul 10